Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Head Neck. 2014 Jul;36(7):1005-12. doi: 10.1002/hed.23404. Epub 2013 Sep 18.

CXC motif ligand 12 as a novel diagnostic marker for papillary thyroid carcinoma.

Author information

  • 1Department of Pathology, Cancer Center, Dongnam Institute of Radiological and Medical Sciences (DIRAMS), Busan, South Korea.

Abstract

BACKGROUND:

We subjected chemokine (C-X-C motif) ligand 12 (CXCL12) to immunohistochemistry to determine its utility as a novel diagnostic marker for papillary thyroid carcinoma (PTC) in comparison to cytokeratin 19 (CK19), Hector Battifora mesothelial epitope-1 (HBME-1), and galectin-3.

METHODS:

We analyzed the expressions of CXCL12, CK19, HBME-1, and galectin-3 using immunohistochemical staining in 258 cases of thyroid lesions (196 PTCs and 62 thyroid lesions excluding PTC).

RESULTS:

Remarkably, CXCL12 expression was exclusively found in PTC compared to other thyroid lesions (90.8% vs 3.2%; p < .001). In total, 91.1% (62 of 68) of the variant PTCs and 90.6% of conventional type (116 of 128) were associated with CXCL12 immunohistochemical expression, irrespective of the histological subtype. In contrast, very few of the thyroid lesions, excluding PTC, were positive for CXCL12 (2 of 62; 3.2%). Diagnostic performances for PTCs were as follows: sensitivity, 90.8%; specificity, 96.8%; positive predictive value, 98.9%; negative predictive value, 76.9%; and diagnostic accuracy, 92.2%.

CONCLUSION:

Our findings indicate that CXCL12 might serve as an effective novel supplementary diagnostic marker for PTC.

Copyright © 2013 Wiley Periodicals, Inc.

KEYWORDS:

CXCL12; diagnostic marker; immunohistochemistry; papillary thyroid carcinoma

PMID:
23784811
[PubMed - in process]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for John Wiley & Sons, Inc.
    Loading ...
    Write to the Help Desk